Tau and 14-3-3 of genetic and sporadic Creutzfeldt-Jakob disease patients in Israel

Zeev Meiner, Esther Kahana, Fanny Baitcher, Amos D. Korczyn, Joab Chapman, Oren S. Cohen, Ron Milo, Judith Aharon-Perez, Oded Abramsky, Ruth Gabizon, Hanna Rosenmann

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


One of the largest clusters of genetic Creutzfeldt-Jakob disease (gCJD) is found among Jews of Libyan origin in Israel and is linked to the E200K mutation in PRNP (gCJDE200K). The aim of this study was to compare the levels of cerebrospinal fluid (CSF) biomarkers, Tau and 14-3-3 proteins, between gCJDE200K patients, sporadic CJD (sCJD) patients and non-CJD controls in Israel between the years 1996-2006. The levels of Tau and 14-3-3 proteins in CSF were measured by ELISA and immunoblotting, respectively. CSF Tau levels were similar in gCJDE200K and sCJD, both were significantly higher than in controls [1,107 ± 470 pg/ml [33/46 (72%)] of the cases > 1,000 pg/ml, 1,280 ± 580 pg/ml [25/30 (83.3%)], and 354 ± 338 pg/ml [17/243 (6.9%)], respectively, p < 0.001]. 14-3-3 was detected in CSF of 41/53 (77%) of each gCJDE200K and sCJD patients tested, but only in 70/417 (16.8%) of controls (p < 0.001). An inverse correlation was found between disease duration and Tau levels in both gCJDE200K and sCJD (r = -0.464 and r = -0.284). No difference was found in Tau or 14-3-3 between the various codon 129 genotypes. We conclude that CSF biomarkers, Tau and 14-3-3, may be used in the diagnosis in both patients' populations, presenting a similar sensitivity yet Tau assay having higher specificity.

Original languageEnglish
Pages (from-to)255-262
Number of pages8
JournalJournal of Neurology
Issue number2
StatePublished - 1 Feb 2011
Externally publishedYes


  • 14-3-3 protein
  • Cerebrospinal fluid
  • Creutzfeldt-Jakob disease
  • Libyan Jews
  • Tau

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Tau and 14-3-3 of genetic and sporadic Creutzfeldt-Jakob disease patients in Israel'. Together they form a unique fingerprint.

Cite this